{"ticker": {"uuid": "e74220b9-ad45-43d2-b784-4a98e023565b", "symbol": "FRE", "name": "Firebrick Pharma Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Enterprise value to EBIT forward of Firebrick Pharma Limited \u2013 ASX:FRE", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQc01qZnl2RkxORkZkZGRIb0FZelVJQ09kYy1iRkNUd0hRZFIxVDlHVGxOOXp6cDRoNGFlUlE1T2dOYWg5VlFVOEpJRHE2WFR5WnFlZEEyaEludVdwZUxxRklWeHlhUGN2cHFCa29tclF4ODY0OWwxc1p0VFlmVTBEMEpSN1BkV1JkVmpqeGN1aHY3UUpFMUFlc3dhQjUyNW8wN3NDSEZn?oc=5", "source_name": "TradingView", "published_at": "2026-07-15T19:05:19+00:00", "published_display": "15 Jul 2026 19:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Biotech Stock Firebrick Pharma (ASX: FRE) Advances on Product Development Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxORWJqQjNoMXpyd29QQURXSkdxanV0NFg0SkRVNHNVYUlEYXNOZ0FBNno4bWhWMUphM2NycWRMbGFZMjdtcERzTlJLR1hSY2IwUWpsemEwTVZSU20xUVRFdWY3MlpJTDFwUnVHOVhGWXU0dVlOb2lVcEhKM3NyZWFrX2QzYUI3NGdkNlh5aWJTS2FFR09iNk9UM1ZkRGxPc1F3ME1NUlluRVJHcXFYWWh0SXBmcldiVS1PS1BvUW9vUQ?oc=5", "source_name": "Kalkine", "published_at": "2026-07-14T03:48:00+00:00", "published_display": "14 Jul 2026 03:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dr Boreham\u2019s Crucible: Friendlier markets lead the way for Firebrick\u2019s respiratory virus killer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNQVQ4OHZDd19WWnJYU21UUXFJVXUyQkozZGhIZTVma1dPamxkdWFxXzdIRVdtTmtBRHBCeXFRUk5aTjRYd2dIMFNVRmFjeENOaWxDTC10VUxRb0R1Z0tzcFYxM2NEcVEzaDdJQ0MybDJkaFM2Q2xPcEpsSmtEbHdTREFTWlREYjlEdHkycWFEd1ZTMlRpLU56SldudWdldmtPZENqT2VzV04xUkd5R3NSSWtvZHRWVXFseWlvenNTODEyZ00?oc=5", "source_name": "Stockhead", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Firebrick Pharma launches antiseptic nasal spray into US online market", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNMmxsOTBYOHk2Uk1FemgzVFVPVXVBeTN0SGxxUEU5TmlsR19kTmVDNENRdTh1TnMwUVNTRGlBOThhT3ItVlFvdV9yeTVqSE42R1V6dGVvRUthN1R5aThZRG5OZFNoRkdWQ1hSX2FxQ09fNHB5WXZ5SkJWZFo3aFphbUZnZnJza0dRaThYaU5XRW9uVkdxTXVtYWRFYXJPa0E?oc=5", "source_name": "smallcaps.com.au", "published_at": "2024-04-17T07:00:00+00:00", "published_display": "17 Apr 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Health Stocks: Firebrick to start Phase 3 trial on common cold spray, MGC Pharma surges 30pc on FDA listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPV0wzV2YyaDBKNFZMZ2QtanJCMHowZUo2dm1LUkNadG56dnREODNIakdqSUZPc2Naa0lBR083UVJYQVJtYUxwQjY0czdWVUVsSFNMOVhRUmtENHYzZUY4MlVKSkU1THVnSTQ4Ny1WX2xhb2M0aWd1ODQwTnJfVHRmTDJNdG9wZlVCc20xcHIyYVdrcFVOdGQtZWJQRDMtT1Q0M1lqeHNUMG0tMTlzbTdkZG45elpnZWNkWDkxZU8xTHZKRjBUa2lONXNhRDdCYW5kODVhbHJfeTBzZw?oc=5", "source_name": "Stockhead", "published_at": "2023-03-21T07:00:00+00:00", "published_display": "21 Mar 2023 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FRE Stock Price and Chart \u2014 ASX:FRE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1kamZxaExDeFdVT3lXNWlackhmQzNvLThBMzYyODlCT2ZOT3dRWjZjQ0dURzgxS3VzX2lmTzd2RGlReHRQNTFiNzl3eXl3SUtUTjE5S1hRTQ?oc=5", "source_name": "TradingView", "published_at": "2022-01-29T13:58:55+00:00", "published_display": "29 Jan 2022 13:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Firebrick Pharma: a two bagger on ASX debut", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxORUpkS19kZ3hoczZjWXo2ZG1QM3NBOWhFQVE1NXpYMHZiOG96RTE5azBEc1dXUkJZYlFaZjRJN25UMlExYW9JWlEtYTVreVpjOG0tckY2dFp2bjFKUUZDZE8xcjdBaDNubnJaVUtZX0hjQl82WTNPMnhreFU2aW1LLTNfemNmaU05SDZLS2tyY01BNlNQWi1vRXVkU3R5OTRKUWdfTjhR?oc=5", "source_name": "Market Index", "published_at": "2022-01-28T08:00:00+00:00", "published_display": "28 Jan 2022 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to EBIT forward of Firebrick Pharma Limited \u2013 ASX:FRE", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQc01qZnl2RkxORkZkZGRIb0FZelVJQ09kYy1iRkNUd0hRZFIxVDlHVGxOOXp6cDRoNGFlUlE1T2dOYWg5VlFVOEpJRHE2WFR5WnFlZEEyaEludVdwZUxxRklWeHlhUGN2cHFCa29tclF4ODY0OWwxc1p0VFlmVTBEMEpSN1BkV1JkVmpqeGN1aHY3UUpFMUFlc3dhQjUyNW8wN3NDSEZn?oc=5", "source_name": "TradingView", "published_at": "2026-07-15T19:05:19+00:00", "published_display": "15 Jul 2026 19:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Biotech Stock Firebrick Pharma (ASX: FRE) Advances on Product Development Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxORWJqQjNoMXpyd29QQURXSkdxanV0NFg0SkRVNHNVYUlEYXNOZ0FBNno4bWhWMUphM2NycWRMbGFZMjdtcERzTlJLR1hSY2IwUWpsemEwTVZSU20xUVRFdWY3MlpJTDFwUnVHOVhGWXU0dVlOb2lVcEhKM3NyZWFrX2QzYUI3NGdkNlh5aWJTS2FFR09iNk9UM1ZkRGxPc1F3ME1NUlluRVJHcXFYWWh0SXBmcldiVS1PS1BvUW9vUQ?oc=5", "source_name": "Kalkine", "published_at": "2026-07-14T03:48:00+00:00", "published_display": "14 Jul 2026 03:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dr Boreham\u2019s Crucible: Friendlier markets lead the way for Firebrick\u2019s respiratory virus killer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNQVQ4OHZDd19WWnJYU21UUXFJVXUyQkozZGhIZTVma1dPamxkdWFxXzdIRVdtTmtBRHBCeXFRUk5aTjRYd2dIMFNVRmFjeENOaWxDTC10VUxRb0R1Z0tzcFYxM2NEcVEzaDdJQ0MybDJkaFM2Q2xPcEpsSmtEbHdTREFTWlREYjlEdHkycWFEd1ZTMlRpLU56SldudWdldmtPZENqT2VzV04xUkd5R3NSSWtvZHRWVXFseWlvenNTODEyZ00?oc=5", "source_name": "Stockhead", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Firebrick Pharma launches antiseptic nasal spray into US online market", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNMmxsOTBYOHk2Uk1FemgzVFVPVXVBeTN0SGxxUEU5TmlsR19kTmVDNENRdTh1TnMwUVNTRGlBOThhT3ItVlFvdV9yeTVqSE42R1V6dGVvRUthN1R5aThZRG5OZFNoRkdWQ1hSX2FxQ09fNHB5WXZ5SkJWZFo3aFphbUZnZnJza0dRaThYaU5XRW9uVkdxTXVtYWRFYXJPa0E?oc=5", "source_name": "smallcaps.com.au", "published_at": "2024-04-17T07:00:00+00:00", "published_display": "17 Apr 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Health Stocks: Firebrick to start Phase 3 trial on common cold spray, MGC Pharma surges 30pc on FDA listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPV0wzV2YyaDBKNFZMZ2QtanJCMHowZUo2dm1LUkNadG56dnREODNIakdqSUZPc2Naa0lBR083UVJYQVJtYUxwQjY0czdWVUVsSFNMOVhRUmtENHYzZUY4MlVKSkU1THVnSTQ4Ny1WX2xhb2M0aWd1ODQwTnJfVHRmTDJNdG9wZlVCc20xcHIyYVdrcFVOdGQtZWJQRDMtT1Q0M1lqeHNUMG0tMTlzbTdkZG45elpnZWNkWDkxZU8xTHZKRjBUa2lONXNhRDdCYW5kODVhbHJfeTBzZw?oc=5", "source_name": "Stockhead", "published_at": "2023-03-21T07:00:00+00:00", "published_display": "21 Mar 2023 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FRE Stock Price and Chart \u2014 ASX:FRE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1kamZxaExDeFdVT3lXNWlackhmQzNvLThBMzYyODlCT2ZOT3dRWjZjQ0dURzgxS3VzX2lmTzd2RGlReHRQNTFiNzl3eXl3SUtUTjE5S1hRTQ?oc=5", "source_name": "TradingView", "published_at": "2022-01-29T13:58:55+00:00", "published_display": "29 Jan 2022 13:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Firebrick Pharma: a two bagger on ASX debut", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxORUpkS19kZ3hoczZjWXo2ZG1QM3NBOWhFQVE1NXpYMHZiOG96RTE5azBEc1dXUkJZYlFaZjRJN25UMlExYW9JWlEtYTVreVpjOG0tckY2dFp2bjFKUUZDZE8xcjdBaDNubnJaVUtZX0hjQl82WTNPMnhreFU2aW1LLTNfemNmaU05SDZLS2tyY01BNlNQWi1vRXVkU3R5OTRKUWdfTjhR?oc=5", "source_name": "Market Index", "published_at": "2022-01-28T08:00:00+00:00", "published_display": "28 Jan 2022 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 77, "total_relevant": 7, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 6, "score": 52, "total": 7, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 88, "events": [{"event": "general", "label": "Market update", "weight": 3.85, "count": 7}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.03, "latest_week": "2026-07-17", "one_week_move": -12.5, "four_week_move": -24.3, "twelve_week_move": -48.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.095567, "market_dynamics_buy_signal": false, "relative_strength": -51.695418, "fair_value_gap": -59.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.4258, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-12.5% over one week, -24.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 2}, {"label": "Stockhead", "count": 2}, {"label": "Kalkine", "count": 1}, {"label": "smallcaps.com.au", "count": 1}, {"label": "Market Index", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 7}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 7}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "88/100 classification confidence."}, {"label": "Company focus", "value": "7", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-12.5% over one week, -24.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to EBIT forward of Firebrick Pharma Limited \u2013 ASX:FRE"}], "updated_at": "2026-07-22T04:14:54.187988+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}